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Objective 
A ‘precision’ approach to type 2 diabetes therapy would aim to target treatment 
according to patient characteristics. We examined if measures of insulin resistance 
and secretion were associated with glycemic response to DPP4-inhibitor therapy. 
Research Design and Methods 
We evaluated whether markers of insulin resistance and insulin secretion were 
associated with 6 month glycemic response in a prospective study of non-insulin 
treated participants starting DPP4-inhibitor therapy (PRIBA, n=254), with replication 
for routinely available markers in UK electronic healthcare records (CPRD, 
n=23,001). In CPRD we evaluated associations between baseline markers and 3 
year durability of response. To test the specificity of findings we repeated analyses 
for GLP-1 receptor agonists (PRIBA n=339, CPRD n=4,464). 
Results 
In PRIBA markers of higher insulin resistance (higher fasting C-peptide (p=0.03), 
HOMA2 insulin resistance (p=0.01) and triglycerides (p<0.01)) were associated with 
reduced 6 month HbA1c response to DPP4 inhibitors. In CPRD higher triglycerides 
and BMI were associated with reduced HbA1c response (both p<0.01). A subgroup 
defined by obesity (BMI≥30kg/m2) and high triglycerides (≥2.3mmol/L) had reduced 6 
month response in both datasets (PRIBA HbA1c reduction 5.3[95%CI 
1.8,8.6]mmol/mol (0.5%) (obese, high triglycerides) vs 11.3[8.4,14.1] mmol/mol 
(1.0%) (non-obese, normal triglycerides), p=0.01. In CPRD the obese, high 
triglycerides subgroup also had less durable response (hazard ratio 1.28[1.16,1.41], 
p<0.001). There was no association between markers of insulin resistance and 
response to GLP-1 receptor agonists.  
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Conclusions 
Markers of higher insulin resistance are consistently associated with reduced 
glycemic response to DPP4-inhibitors. This finding provides a starting point for the 
application of a precision diabetes approach to DPP4-inhibitor therapy.  
PRIBA ClinicalTrials.gov identifier: NCT01503112  
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Type 2 diabetes is a heterogeneous condition characterised by varying degrees of 
reduced beta cell function and higher levels of insulin resistance. Most of the 400 
million patients worldwide will at some point require glucose lowering medication (1). 
Major international treatment guidelines recommend at least 4 oral treatment options 
after initial metformin has failed to achieve control, with choice between these 
informed predominantly by method of administration, overall side effect profile and 
cost (2-5). 
Individual response to glucose lowering therapies in type 2 diabetes varies greatly. 
Identification of clinical phenotypic features or biomarkers robustly associated with 
glycemic response or other potentially beneficial effects for example reduced weight 
gain, or side effects for each therapy, may allow treatment of patients with the agent 
that is most likely to be effective for them, an approach known as ‘precision’ or 
‘stratified’ medicine (6; 7). While much research has focused on identifying genetic or 
novel biomarker predictors of response, precision diabetes is most likely to be cost 
effective and have clinical impact using simple inexpensive biomarkers or routinely 
available clinical phenotypic features (8; 9).  
DPP4 inhibitors are common (20% of U.S. and 40% of UK second-line prescriptions 
in 2016) (10; 11), well-tolerated (12), oral therapy options recommended in all clinical 
guidelines (2-5). Beyond baseline HbA1c and fasting glucose it is unclear if other 
factors are associated with glycemic response to DPP4 inhibitors (13; 14). A major 
mechanism of action of DPP4 inhibitors is potentiation of beta cell insulin secretion. 
We aimed to establish if measures of insulin secretion and insulin resistance were 
associated with short-term glycemic response and long-term durability of response in 
patients with type 2 diabetes starting DPP4 inhibitor therapy.  
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Research Design and Methods 
We assessed whether clinical features and biomarkers associated with insulin 
secretion and insulin resistance were predictive of short-term 6 month glycemic 
response in analysis of a prospective study of patients starting DPP4 inhibitor 
therapy as part of routine care (PRIBA). To validate our findings we tested the 
consistency of associations between routinely recorded factors associated with 
response in PRIBA in a retrospective analysis of a much larger group of patients 
from UK Clinical Practice Research Datalink (CPRD), evaluating both 6 month 
glycemic response and long term durability of response to 3 years. 
Study setting and assessment  
PRIBA prospective study 
The PRIBA study was designed to test the hypothesis that those who have low 
insulin secretion, as measured by C-peptide, will have poor glycemic response to 
incretin based treatments (https://clinicaltrials.gov/ct2/show/NCT01503112), with 
associations between glycemic response and other clinical features, islet 
autoantibodies and Homeostasis Model Assessment (HOMA) 2 estimates of beta 
cell function and insulin sensitivity evaluated in pre-specified secondary analysis. 
305 participants due to start DPP4 inhibitor therapy as part of their usual care were 
recruited from primary and secondary care across 17 National Institute of Health 
Research (NIHR) clinical research network centres in the UK from April 2011 to 
October 2013 as previously described (15).  
At baseline (immediately prior to starting therapy) we measured HbA1c, fasting 
glucose, clinical markers of insulin resistance and insulin secretion (fasting C-peptide 
and post meal urine C-peptide Creatinine ratio (UCPCR) (16; 17); BMI, triglycerides 
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and HDL-cholesterol (HDL-c) (18); sex-hormone binding globulin (SHBG), GAD and 
IA2 islet autoantibodies) and other clinical characteristics (age at therapy, sex, 
duration of diabetes, eGFR, ethnicity, LDL-cholesterol (LDL-c), number of diabetes 
therapies). We calculated HOMA-estimates of beta-cell function (HOMA2%B) and 
insulin resistance (HOMA2 IR) from fasting glucose and C-peptide measures using 
the HOMA2 calculator available from http://www.dtu.ox.ac.uk/homacalculator/ (19). 
Laboratory analysis was conducted as previously reported (15). Participants were 
included in the analysis if they were not insulin treated and had at least 3 months 
follow up with >75% adherence to therapy and limited co-treatment change (see 
study profile supplementary figure 1a). Ethics approval was granted by the South 
West National Research Ethics committee, and all participants gave written informed 
consent.  
Retrospective analysis of UK primary care patients (CPRD database) 
CPRD is the world’s largest longitudinal database of anonymised primary care 
electronic health records (20). We included 23,001 non-insulin treated patients with 
type 2 diabetes with prescription records of starting a DPP4 inhibitor for the first time 
from June 2007 to September 2016, and followed them up whilst they remained on 
DPP4 inhibitor therapy without the addition or cessation of any other anti-
hyperglycemic medication (see study profile supplementary figure 1b). We extracted 
baseline routine clinical characteristics (age at therapy, duration of diabetes, sex and 
BMI) and biomarkers (HbA1c, triglycerides, HDL-c, LDL-c and eGFR), with baseline 
defined as the most recent record in the 3 months prior to the drug start date. Ethics 
approval was granted by the CPRD Independent Scientific Advisory Committee 
(ISAC 13_177R). 
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Analysis 
Outcome definitions 
Short-term glycemic response (PRIBA & CPRD) 
The primary outcome was the absolute change from baseline in HbA1c 6 months 
after starting therapy, adjusting for baseline HbA1c. Where a 6 month HbA1c was not 
available or eligible in the PRIBA study (see supplementary figure 1a) we used a 3 
month HbA1c measure, as previously described (15). In CPRD a valid 6 month HbA1c 
was defined as the closest HbA1c to 6 months after the drug start date +/-3 months 
for patients on unchanged anti-hyperglycemic therapy.  
Durability of glycemic response (CPRD) 
In CPRD where long-term follow-up data were available we assessed durability of 
response as the time to glycemic failure over 3 years in a complete case analysis of 
patients with baseline HbA1c between 53-97 mmol/mol (7-11%) and at least 3 months 
on DPP4 inhibitor therapy (n=15,616). Glycemic failure was defined as a) two 
consecutive HbA1c’s greater than 69 mmol/mol (8.5%) b) a single HbA1c greater than 
69 mmol/mol (8.5%) followed by the addition of another anti-hyperglycemic therapy. 
To examine the sensitivity of results to this definition we repeated the analysis using 
HbA1c thresholds of a) 53mmol/mol (7.5%) and b) the baseline HbA1c level specific to 
each individual patient. 
Statistical analysis 
Short-term response (PRIBA & CPRD) 
We examined associations between each standardised marker of insulin resistance 
and insulin secretion and 6 month HbA1c response in a series of linear regression 
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models adjusted for baseline HbA1c and, in PRIBA, co-therapy change (13; 20). Non-
normally distributed variables were log-transformed. We conducted a complete case 
analysis for each marker, including all patients with valid data even if they had 
missing data for other markers. To evaluate model fit we examined normality of 
residuals and linearity of associations for continuous variables. In both datasets we 
tested the independence of initial associations for each marker of insulin resistance 
and insulin secretion with 6 month response in further multivariable analysis, 
controlling for baseline HbA1c and other routinely recorded characteristics: age at 
therapy, duration of diabetes, sex, eGFR, LDL-c, ethnicity (CPRD only: white, non-
white, missing) and co-therapy change (PRIBA only, CPRD patients all on 
unchanged therapy). 
To further assess the robustness of findings we repeated the baseline adjusted 
analysis of 6 month response for males and females separately in both datasets, and 
in PRIBA with additional adjustment for fasting glucose. In CPRD we repeated the 
baseline adjusted analysis using 12 month response as the outcome in a distinct 
cohort of patients with 12 month (closest +/-3 months as for definition of 6 month 
response) HbA1c record (n=16,166).  
Subgroup analysis of short-term response (PRIBA & CPRD) 
Based on the initial results we defined 3 patient subgroups by standard clinical cut-
offs for obesity (BMI>=30 kg/m2) and high triglycerides (>=2.3mmol/L) (21) - Group 
A: non-obese and normal triglycerides, Group B: non-obese OR normal triglycerides, 
Group C: obese and high triglycerides.  We estimated the mean 6 month HbA1c 
response for each subgroup using linear regression models adjusted for baseline 
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HbA1c and, in PRIBA, co-therapy change. We standardised baseline HbA1c to the 
mean PRIBA baseline level of 74mmol/mol (8.9%) for all subgroups in both datasets.  
Durability of response (CPRD) 
For 3 subgroups defined by the same BMI and triglyceride thresholds we compared 
mean durability in response to three years after starting therapy using a flexible 
parametric time to failure survival model. We included all patients with at least 3 
months on therapy after starting a DPP4 inhibitor with valid baseline records of all 
covariates (baseline HbA1c, age at therapy, duration of diabetes, sex and eGFR). 
The use of flexible parametric models allowed prediction of the probability of therapy 
failure over three years as well as hazard ratios consistent with Cox proportional 
hazards regression (22). We tested continuous variables for non-linearity, and 
evaluated proportional hazards assumptions using Schoenfeld residuals. To 
estimate the probability of therapy failure (the inverse of survival) for each subgroup 
a predicted survival curve was calculated for each patient in the dataset before the 
individual survival curves for all patients within a subgroup were averaged (23). Each 
curve was standardised to the mean CPRD values of other clinical covariates 
(baseline HbA1c = 72mmol/mol (8.7%), age at therapy = 64 years, duration of 
diabetes = 8 years, eGFR = 82 ml/min/1.73m2). Point estimates for the failure 
probability at 3 years by subgroup were calculated using the same approach. 
Replication analysis with GLP-1 receptor agonists (PRIBA and CPRD) 
To test the specificity of findings for DPP4 inhibitors we repeated the analyses of 
short-term response and durability of response for non-insulin treated subjects 
starting GLP-1 receptor agonists, the other glucose-lowering drug evaluated in 
PRIBA (PRIBA n=339, CPRD n=4,464). We have previously reported the PRIBA 
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primary analysis of predictors of glycemic response for the full PRIBA GLP-1 
receptor agonist cohort, which included an additional 209 insulin treated participants 
(14).  All data extraction and analysis were conducted using Stata v14.0 (StataCorp, 
College Station, TX). 
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Results 
Patient characteristics & response to DPP4 inhibitor therapy 
Baseline characteristics and biomarker measures were similar for subjects starting 
DPP4 inhibitors in both datasets (Table 1). In both cohorts the majority of patients 
started Sitagliptin. 254 patients were included in PRIBA and 23,001 (for analysis of 6 
month glycemic response) in CPRD (for study profiles see supplementary figure 1). 
Mean (standard deviation (SD)) 6 month HbA1c change was -8.3 (13.5) mmol/mol (-
0.7% (1.2%)) in PRIBA and -7.6 (15.1) mmol/mol (-0.7% (1.4%)) in CPRD.  
Higher baseline fasting C-peptide and HOMA measured insulin resistance are 
associated with reduced glycemic response to DPP4 inhibitors  
In the PRIBA cohort mean HbA1c response was reduced by 1.67 mmol/mol for every 
1 SD higher baseline fasting C-peptide (standardised β 1.67 [95% CI 0.17 to 3.17] 
mmol/mol/SD, p=0.03) (Figure 1). We observed the same direction and similar size 
of effect for UCPCR (response reduction per SD higher 1.65 [95% CI -0.07 to 3.37] 
mmol/mol, p=0.06). Higher baseline HOMA measured insulin resistance (HOMA2-IR) 
was also associated with reduced response (response reduction per SD higher: 2.17 
[95% CI 0.62 to 3.72], mmol/mol, p=0.01), but there was no evidence of an 
association between beta-cell function (HOMA2-%B) and response (response 
reduction per SD higher 0.16 [95% CI -1.49 to 1.81] mmol/mol, p=0.85). Islet 
autoantibody prevalence was low (2.8% GAD or IA2 positive; response reduction for 
presence of autoantibodies: 5.6 [95% CI -3.6, 14.7] mmol/mol, p=0.23). 
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Other markers of insulin resistance are consistently associated with glycemic 
response to DPP4 inhibitors in PRIBA and CPRD  
In PRIBA higher triglycerides was associated with reduced glycemic response 
(response reduction per SD increase 2.54 [95% CI 0.99 to 4.08] mmol/mol, p<0.001), 
with a consistent direction of association for higher BMI (response reduction per  
higher BMI 0.96 [95% CI -0.54 to 2.46] mmol/mol, p=0.21) and lower SHBG 
(response reduction per SD higher SHBG -1.19 [95% CI -2.81 to 0.42] mmol/mol, 
p=0.15) (Figure 1, supplementary table 1). In CPRD higher triglycerides and BMI 
were associated with reduced HbA1c response (Figure 1, supplementary table 1). 
HDL-c was not associated with response in either dataset (p=0.81 in PRIBA, p=0.46 
in CPRD). 
Markers of insulin resistance are associated with glycemic response to DPP4 
inhibitors independently of other routine clinical characteristics 
Results were consistent when a) stratifying by sex (supplementary table 1), b) 
controlling for baseline HbA1c, age at therapy, sex, duration of diabetes, eGFR, LDL-
c, ethnicity (CPRD only) and co-therapy change (PRIBA only) in multivariable 
analysis of each dataset (supplementary table 2), c) in PRIBA controlling for fasting 
glucose (supplementary table 3) and d) in CPRD with 12 month HbA1c response as 
the outcome (supplementary table 4). 
Standard clinical criteria of obesity and high triglycerides can identify patients 
likely to have markedly reduced glycemic response to DPP4 inhibitors 
Higher triglycerides was associated with reduced glycemic response independently 
of BMI in both datasets, and higher BMI was associated with reduced response 
independently of triglycerides in CPRD (supplementary table 5). To examine the 
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potential clinical implication of this finding we compared mean baseline HbA1c 
adjusted response in 3 patient subgroups defined by standard clinical cut-offs for 
obesity (BMI>=30 kg/m2) and high triglycerides (>=2.3mmol/L) - Subgroup A: non-
obese and normal triglycerides, Subgroup B: non-obese OR normal triglycerides, 
Subgroup C: obese and high triglycerides).   
In PRIBA we found mean 6 month baseline HbA1c standardised glycemic response 
was halved for the obese and high triglycerides subgroup (Subgroup C -5.2 [95% CI 
-1.8 to -8.6] mmol/mol (-0.5% [95% CI -0.2;-0.8])) compared to the non-obese and 
normal triglycerides subgroup (Subgroup A -11.3 [95% CI -8.4 to -14.1] mmol/mol (-
1.0% [95% CI -0.8;-1.3])) and was significantly reduced compared to intermediate 
Subgroup B (-9.9 [95% CI -7.6 to -12.2] mmol/mol (-0.9% [95% CI -0.7;-1.1])) (Figure 
2a). Direction of effect was replicated in CPRD, albeit with smaller differences in 
mean response between subgroups (Subgroup A mean baseline adjusted HbA1c 
response -10.3 [95% CI -9.8 to -10.7] mmol/mol (-0.9% [95% CI -0.9;-1.0]), 
Subgroup B -8.8 [95% CI -8.5 to -9.1] mmol/mol (-0.8% [95% CI -0.8;-0.8]), 
Subgroup C -7.5 [95% CI -7.0 to -7.9] mmol/mol (-0.7% [95% CI -0.6;-0.7]), Figure 
2b). 
 
Obesity and high triglycerides are associated with less durable glycemic 
response to DPP4 inhibitors over 3 years  
15,616 patients were followed up in this analysis for a mean time of 1.5 years. Over 
the 3 year study period 3,514 (23%) patients had glycemic failure (confirmed HbA1c 
≥ 69 mmol/mol (8.5%). We observed an increased relative risk of glycemic failure , 
reflecting a less durable response) in the same obesity and high triglycerides defined 
subgroups, standardising for other clinical characteristics (hazard ratios for glycemic 
14 
 
failure: Subgroup C obese AND high triglycerides versus Subgroup A non-obese and 
normal triglycerides 1.28 [95% CI 1.16-1.41], p<0.001; Subgroup B obese OR high 
triglycerides versus Subgroup A 1.17 [95% CI 1.08-1.27], p<0.001; Subgroup C 
versus Subgroup B 1.09 [95% CI 1.01-1.18], p=0.04; supplementary table 6). 
Consistent relative differences between subgroups were observed at HbA1c failure 
thresholds of 7.5% and the baseline HbA1c specific to each individual patient 
(supplementary table 7-8). These results translated into significant differences 
between subgroups in the absolute probability of glycemic failure at three years 
(Subgroup C: obese AND high triglycerides 39% [95% CI 37-42%]; Subgroup B: 
obese OR high triglycerides 37% [95% CI 35-38%]; Subgroup A: non-obese and 
normal triglycerides 32% [95% CI 31-34 %] supplementary figure 2).  
There is no evidence of an association between markers of insulin resistance 
and glycemic response to GLP-1 receptor agonists 
We found no evidence of an association between any marker of insulin resistance 
and 6 month glycemic response to GLP-1 receptor agonists in PRIBA (n=339) or 
CPRD (n=4,464) on continuous analysis (Figure 3, supplementary tables 8-9). There 
was also no evidence for a difference in response to GLP-1 receptor agonists across 
the obesity and triglyceride defined subgroups (all subgroup comparisons p>0.40; 
supplementary table 10, supplementary figure 3), although there were few subjects 
in the non-obese, normal triglyceride subgroup starting GLP-1 receptor agonist 
therapy in both datasets (PRIBA 2%, CPRD 5%). Similarly, in CPRD we found no 
evidence of an association between durability of glycemic response and BMI (HR per 
unit increase 1.01 (95% CI 1.00-1.02, p=0.29) or triglyceride levels (HR per unit 
increase 0.99 (95% CI 0.95-1.04, p=0.80) (supplementary table 10), or of a 
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difference in durability of response across obesity and triglyceride defined subgroups 
(supplementary table 11, supplementary figure 4). 
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Conclusions 
Our results show that markers of higher insulin resistance are consistently 
associated with reduced glycemic response to DPP4 inhibitor therapy. In our UK-
representative cohort 22% of patients were obese with high triglycerides 
(≥2.3mmol/L) and these patients had both markedly reduced short-term glycemic 
response and shorter durability of response on DPP4 inhibitor treatment. With GLP-1 
receptor agonists we found no evidence of an association between markers of 
insulin response and either 6 month glycemic response or durability of response to 3 
years. Findings were robustly demonstrated in a prospective study and validated in 
real-world data and provide a starting point for the application of a precision diabetes 
approach with DPP4 inhibitor therapy.  
Strengths of this study include that we have shown consistent findings across 
several clinical features and markers of insulin resistance in a prospective study and 
large dataset of electronic healthcare records. We have shown findings are robust 
with adjustment for baseline HbA1c (13; 24), and potential confounders, and by 
definition of glycemic response, with similar associations for short term (6 and 12 
month) and long term (3 year durability) glycemic outcomes. Our study is the first to 
identify characteristics associated with durability of response to DPP4 inhibitor 
therapy, an area where evidence is limited (25). 
Limitations of this study include that we were only able to partially replicate our 
results from the PRIBA study cohort, as measures such as C-peptide were not 
available in our replication dataset. Our effect size for triglycerides is notably smaller 
in our replication dataset. It is possible this relates to differences in triglyceride 
measurement (we were unable to confirm if measured triglycerides were fasted in 
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these real-world data) or to increased error in electronic healthcare records in 
comparison to the prospective study (26), or to the effect of statistical chance in the 
smaller dataset. The only long-term follow-up data we had to evaluate durability of 
glycemic response was from the routine primary care dataset CPRD, further 
evaluation in a trial setting with greater follow-up than PRIBA would be of 
considerable interest. An additional important limitation is that this study has 
examined response to only two of the available therapies. Evidence is limited for 
other therapies, although a previous study found no evidence of a relationship 
between clinical insulin resistance or dyslipidaemia markers and glycemic response 
with the SGLT-2 inhibitor Dapaglifozin (27).  High BMI and triglycerides have both 
been shown to be associated with modest increases in the rate of diabetes 
progression (28). While this is unlikely to be relevant to our finding for 6 month 
glycemic response this could influence our findings for treatment durability, and 
replication looking at other comparison therapies is therefore particularly important in 
this context. While we have only examined relatively crude measures of insulin 
resistance, for clinical practice we consider it very unlikely that more complex 
measures would ever be feasible (29).  
Existing studies of the association between insulin resistance and short-term 
glycemic response to DPP4 inhibitors have not shown consistent findings and are 
constrained by methodological and reporting limitations, as recently reviewed by 
Bihan and colleagues (13). Meta-regression of study level data have suggested 
reduced glycemic response in patients with higher BMI in one study (30), but no 
relationship in another analysis (31). These studies should be interpreted with some 
caution due to risk of ecological bias (32; 33). A number of individual clinical trials of 
DPP4 inhibitors have commented on consistency of glucose response across 
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subgroups defined by baseline BMI or insulin resistance, reduced glycemic response 
with high HOMA measured insulin resistance was reported in 2 of 7 studies, and 
reduced response with high BMI in 6 of 36 studies, as reviewed in Bihan et al (13). 
No studies reported an opposite direction of effect.  These reports are very limited, 
with the vast majority providing no statistical comparison or details of what analysis 
was undertaken.  An important issue for analysis of this nature is accounting for the 
influence of baseline HbA1c, the strongest predictor of glycemic response, which may 
confound true associations, especially as baseline HbA1c and insulin resistance are 
positively correlated (24; 34; 35). There are limited data examining the relationship 
between triglycerides and response to DPP4 inhibitors, however one study stratified 
patients by baseline triglycerides (</>1.7mmol/l) and found the odds of achieving an 
HbA1c target of 53mmol/mol (7%) were doubled in the low triglyceride subgroup (OR 
2.2 [95% CI 1.0-4.7], p=0.04) (36). 
While it is plausible our finding of reduced glycemic response in those with high BMI 
or high triglycerides directly relates to insulin resistance through reduced effect of 
drug potentiated insulin secretion, this effect is not apparent in other drugs with 
effects on insulin secretion, for example there is no relationship between obesity and 
response to sulfonylurea therapy or GLP-1 receptor agonists (15; 37). An alternative 
explanation would be a direct effect of lipotoxicity, or indirect associations with other 
(unmeasured) factors important to DPP4 inhibitor response. A direct mechanism for 
lipotoxicity in reducing response to incretin based therapy has been previously 
suggested, with expression of GLP1 receptors diminished in islets exposed to 
elevated fatty acid levels in animal models, and beta cell response to GLP1 restored 
following fatty acid reduction with fibrate pharmacotherapy, however this mechanism 
would not explain the  lack of an association between these features and GLP-1 
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Receptor Agonist response(38). It has also been shown that GLP-1 response is 
blunted in obese insulin resistant patients with high liver fat and also blunted in 
patients with high fasting triglycerides (39; 40), therefore impaired GLP-1 secretion in 
obese insulin resistant individuals represents a potential indirect mechanism that 
could also account for the lack of a similar relationship for injected GLP-1 receptor 
agonist therapy. While the lack of association for HDL-c may be considered 
unexpected, we note HDL-c has a much weaker relationship with insulin resistance 
than either triglycerides or fasting insulin/C-peptide, which may explain this finding 
(18).  
Our findings have potential implications for clinical practice, as both BMI and 
triglycerides are routinely available at no additional cost. Stratification of treatment 
based on these criteria may therefore be cost effective even with the more modest 
differences in treatment effect seen in our replication cohort.  Although our own and 
previous research suggests these findings may be specific to DPP4 inhibitors further 
work examining the relationship between these, and other, factors and response to 
comparator drugs is needed. Our study design, emphasising the importance of 
replication across datasets, provides an exemplar for such future analyses. In 
addition while simple categorisation by subgroup may provide a starting point for 
prediction of therapy response in type 2 diabetes, we anticipate a more sophisticated 
precision diabetes approach combining features into a multivariable response 
calculator will have greatest clinical utility, and this this is an important area for future 
research (8; 41). 
In conclusion, our study shows simple markers of higher insulin resistance are 
consistently associated with reduced glycemic response to DPP4 inhibitor therapy. 
This finding was robustly demonstrated in a prospective study and validated in real-
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world data and provide a starting point for the application of a precision diabetes 
approach to DPP4 inhibitor therapy in type 2 diabetes.  
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Table 1: Subject baseline characteristics  
 
 PRIBA 
(n=254) 
CPRD  
(n=23,001) 
Characteristics  
mean (SD) unless stated     
Baseline HbA1c (mmol/mol)  74 (12) 72 (15) 
Baseline HbA1c (%)  8.9 (1.1) 8.7 (1.3) 
Age at therapy start (years)  63 (10) 64 (11) 
Age at diagnosis (years)  54 (10) 56 (10) 
Male sex (%)  63% 61% 
Duration of diabetes (years)  9 (6) 8 (5) 
BMI - median (IQR); mean(SD)  32 (29-37); 33 (6) 32 (28-36); 33 (6) 
Ethnicity (%)    
White  97% 45% 
Non-White  3% 6% 
Missing  0% 49% 
    
Biomarkers 
median (IQR); mean (SD) unless stated    
*=log-transformed    
Triglycerides (mmol/L)  1.7 (1.2-2.4); 1.8 (0.9)* 1.8 (1.3-2.6); 1.9 (1.0)* 
HDL-c (mmol/L)  1.1 (0.9-1.3); 1.1 (0.3)* 1.1 (0.9-1.3); 1.1 (0.3)* 
LDL-c (mmol/L)  1.9 (1.5-2.3); 1.9 (0.8)* 2.1 (1.6-2.6); 2.0 (0.8)* 
SHBG (nmol/L)  27 (19-41); 27 (16)* NA 
Fasting C-peptide (pmol/L)  1150 (820-1460); 1090 (480)* NA 
HOMA2-%B   54 (37-73); 51 (27)* NA 
HOMA2 IR  3.1 (2.3-4.2); 3.1 (1.5)* NA 
UCPCR nmol/mmol  3.4 (2.0-5.0); 3.0 (2.3)* NA 
eGFR (ml/min/1.3m2)  85 (70-98); 85 (24) 82 (66-97); 82 (23) 
GAD or IA2 positive (%)  3% NA 
    
Therapy      
Number of concomitant therapies at 
therapy start (% of total) 
 
  
0  3% 6% 
1  35% 51% 
2  57% 42% 
3+  5% 2% 
DPP4 type (% of total)    
Sitagliptin  87% 72% 
Alogliptin  0% 2% 
Linagliptin  4% 10% 
Saxagliptin  6% 12% 
Vildagliptin  2% 4% 
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Figure legends 
Figure 1: DPP4 inhibitors - associations between markers of insulin resistance 
and HbA1c response at 6 months. Circles (black = PRIBA, white = CPRD) denote 
the mean HbA1c change (mmol/mol) at 6 months per 1 standard deviation (SD) 
higher baseline value of each marker. Error bars denote 95% confidence intervals.  
 
Figure 2: DPP4 inhibitors - predicted mean absolute HbA1c change from 
baseline at 6 months in a) PRIBA b) CPRD across subgroups defined by the 
presence or absence of obesity (BMI>=30 kg/m2) and high triglycerides (TRGs 
>=2.3mmol/L) - Subgroup A: non-obese and normal triglycerides, Subgroup B: 
non-obese OR normal triglycerides, Subgroup C: obese and high triglycerides. 
Baseline HbA1c is standardised to the mean PRIBA baseline level of 74mmol/mol 
(8.9%) for all subgroups. Error bars denote 95% confidence intervals.  
 
Figure 3: GLP-1 receptor agonists - associations between markers of insulin 
resistance and HbA1c response at 6 months. Circles (black = PRIBA, white = 
CPRD) denote the mean HbA1c change (mmol/mol) at 6 months per 1 standard 
deviation (SD) higher baseline value of each marker. Error bars denote 95% 
confidence intervals. 
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